Royal Bank of Canada Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $136.00
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $143.00 to $136.00 in a report released on Thursday morning, Benzinga reports. The firm currently has a sector perform rating on the stock. Several other equities analysts also recently issued reports on the company. StockNews.com upgraded Neurocrine Biosciences […]
More Stories
US Homebuilders Lean on Incentives to Unload Homes in Challenging Market
By Panos Mourdoukoutas Homebuilder earnings reports released in recent days point to a challenging environment for the industry, as companies...
Shell to Buy ARC Resources in $16.4 Billion Deal to Expand Canada Output
By Bill Pan Shell is set to buy ARC Resources in a move that would expand the British oil major’s...
White House to Hold Meeting on Security Protocols After Shooting, Official Says
By Jack Phillips White House chief of staff Susie Wiles will hold a meeting with the Secret Service and the...
Trump Says First Lady Unharmed, ‘Doing Great’ After White House Correspondents’ Dinner Shooting
By Jack Phillips President Donald Trump on Sunday morning said that First Lady Melania Trump is doing “doing great” and...
People Are Losing Billions Through Social Media Scams, FTC Says
By Jackson Richman Americans are losing billions of dollars to scams that begin on social media, according to new data...
US Accuses China of ‘Industrial-Scale’ AI Theft Ahead of Trump’s Visit
By Michael Zhuang The White House has issued a sharply worded memo accusing China-linked entities of systematically stealing U.S. artificial...